Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

NCT ID: NCT01857817

Last Updated: 2018-04-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-06-30
• Study Completion Date: 2016-04-30

Brief Summary

The purpose of this study is to evaluate the clinical benefit of the co-administration of propranolol and etodolac (VT-122 therapy) in patients with clinically progressive prostate cancer.

Conditions

Prostatic Neoplasms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

VT-122 with physician's choice therapy

Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.

Group Type: EXPERIMENTAL

VT-122

Intervention Type: DRUG

The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.

Placebo with physician's choice therapy

Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

The placebo capsules will be prepared to match the active drug.

Interventions

VT-122

The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.

Intervention Type: DRUG

Placebo

The placebo capsules will be prepared to match the active drug.

Intervention Type: DRUG

Other Intervention Names

propranolol; etodolac

Eligibility Criteria

Inclusion Criteria

1. Have a confirmed diagnosis of prostate cancer

2. Male participants who are ≥18 years of age

3. In the opinion of the investigator, the participants have a life expectancy of at least 3 months.

4. Two consecutively rising PSA values or two out of three rising PSA values (2.0 ng/mL is the minimum ending value for PSA) at a minimum of 1-week intervals

5. Have a Karnofsky Performance Score (KPS) equal to or greater than 70

6. Have the following laboratory parameters (may be assessed locally):

1. Platelet count ≥50 x 10E3/µL

2. Total bilirubin ≤1.5 mg/dL

3. Serum creatinine ≤1.5 x upper limit of normal (ULN) or creatinine clearance >60 mL/min calculated using Cockcroft-Gault

4. Liver enzymes [aspartate transaminase (AST), alanine transaminase (ALT)] ≤2 x ULN

7. Able to provide written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, for any reason without prejudice

Exclusion Criteria

1. The patient has a history of another primary cancer, with the exception of:

1. Curatively resected non-melanomatous skin cancer;

2. Other primary solid tumor with no known active disease presents that in the opinion of the investigator that will not affect patient outcome in the setting of current prostate cancer diagnosis.

2. Contraindication to propranolol, etodolac

3. Patients on beta blockers

4. Patients receiving chemotherapy (e.g., docetaxel, cabazitaxel, taxane, or platinum as single agents or in combination) as their cancer treatment

5. History or evidence of cardiac disease: congestive heart failure; New York Heart Association class 2 or greater; active coronary artery disease; unstable angina, cardiac arrhythmias requiring anti-arrhythmic therapy, atrio-ventricular block of second or third degree, or uncontrolled hypertension, patients with recent (less than 6 months) myocardial infarction (MI) or coronary revascularization

6. Hypotension at the time of screening (i.e., systolic blood pressure less than 110 mmHg. Diastolic blood pressure less than 60 mmHg)

7. Resting heart rate less than 60 bpm at time of screening

8. Any uncontrolled, intercurrent illness that in the opinion of the Investigator may interfere with study evaluation. Participants with uncontrolled diabetes will be excluded from the study.

9. On chronotropic drugs (acetylcholine, digoxin, diltiazem, verapamil, atropine, dopamine, dobutamine, epinephrine, isoproterenol)

10. Active clinically serious infections [> Grade 2 National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0]

11. Substance abuse, medical, psychological or social conditions that may, in the opinion of the investigator, interfere with the patient's participation in the study or evaluation of the study results

12. Known or suspected allergy to the investigational agents or any agent given in association with this trial (hypersensitivity reaction, hives, rash, difficulty breathing swelling of your face, lips, tongue, or throat)

13. Any condition that is unstable or which in the opinion of the Investigator could jeopardize the safety of the patient and his/her compliance in the study

14. Patients with uncontrolled diabetes or insulin resistance

15. Participation in any other investigational trial in which receipt of investigational drug or device occurred within 30 days prior to screening for this study

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Vicus Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Highlands Oncology Group

Fayetteville, Arkansas, United States

Redwood Regional Medical Group

Santa Rosa, California, United States

Advanced Urology

Parker, Colorado, United States

Manatee Medical Research Institute, LLC

Bradenton, Florida, United States

Baptist Cancer Institute

Jacksonville, Florida, United States

Midwestern Regional Medical Center

Zion, Illinois, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Detroit Clinical Research Center, PC

Lansing, Michigan, United States

Adult & Pediatric Urology

Sartell, Minnesota, United States

AccuMed Research Associates

Garden City, New York, United States

Premier Medical Group of the Hudson Valley PC

Poughkeepsie, New York, United States

Montefiore Medical Center

The Bronx, New York, United States

Hendrick Cancer Center

Abilene, Texas, United States

Oncology Consultants, P.A.

Houston, Texas, United States

Virginia Mason Medical Center

Seattle, Washington, United States

Medical Oncology Associates, PS

Spokane, Washington, United States

Countries

United States

Other Identifiers

VT1-SYS-601

Identifier Type: -

Identifier Source: org_study_id